Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® ...

Objectives This study aims to study the association between socioeconomic factors and risk of prevalent eye diseases, ...

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) rose 10% Wednesday after the company reported positive six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic ...